sitefansalaran International News

A case of the flesh-eating screwworm parasite has been identified in a person in Maryland who had traveled to the United States from Guatemala, according to four sources familiar with the situation. The person, who received treatment in Maryland, is the first new confirmed case this year in the U.S. of New World screwworm, a parasite that eats cattle and other warm-blooded animals alive, as an outbreak escalates and moves northward from Central America and southern Mexico. Beth Thompson, South Dakota's state veterinarian, told Reuters on Sunday that she was notified of the case within the last week by a person with direct knowledge of the Maryland case. A second source, who asked not to be identified, said they had seen emails sent by an executive of the industry group Beef Alliance on August 20 to about two dozen people in the livestock and beef sectors, informing them that the U.S. Centers for Disease Control and Prevention had confirmed a human case of screwworm in Maryland in a person who had traveled to the U.S. from Guatemala. State veterinarians learned about the human case in Maryland during a call last week with the CDC, according to one source. A Maryland state government official...

Saudi Arabia’s Health Ministry has announced strict new penalties targeting health practitioners and facilities that prescribe or dispense weight-loss injections without medical supervision, citing serious risks to public health. The ministry said offenders could face fines of up to 100,000 riyals, revocation of their licenses, and up to six months in prison. The crackdown, part of a wider inspection campaign, also prohibits marketing weight-loss drugs without a valid prescription. Health officials warned that unsupervised use of such medications can cause dangerous side effects, including rapid heart rate, low blood sugar, and pancreatitis. Long-term or unmonitored use could lead to chronic conditions such as digestive disorders and higher risk of weight regain once treatment stops. The announcement comes as obesity rates rise in the kingdom. According to the Saudi General Authority for Statistics, 23.1 percent of residents aged 15 and older are obese, while 45.1 percent are overweight. Many patients are increasingly turning to unprescribed weight-loss drugs, heightening fears among health experts about long-term safety. The ministry urged the public to seek medical advice before using such treatments and called on pharmacies and practitioners to strictly follow regulations on dispensing. It pledged to continue inspection campaigns and to take action against violators, including imposing financial penalties and withdrawing...

At least 600 employees of the U.S. Centers for Disease Control and Prevention are receiving permanent termination notices, the Associated Press reported on Wednesday, citing the American Federation of Government Employees. The report added that the notices were sent out this week, and many employees have not yet received them, according to the employees' union, which represents more than 2,000 dues-paying members at the agency. A spokesperson for the U.S. Department of Health and Human Services confirmed the terminations but did not disclose the number of employees affected. The union did not immediately respond to a Reuters request for comment. The Trump administration began mass layoffs of 10,000 staffers at U.S. health agencies in April, as part of a sweeping overhaul aimed at shrinking the federal government and reducing spending. A federal judge last week issued a preliminary ruling that protected employees in several parts of the CDC, including those dealing with sexually transmitted diseases, reproductive health, environmental health and birth defects, among others. However, the ruling did not protect other CDC employees, and layoffs are being finalized across other parts of the agency, including the freedom of information office, the AP report added. "Due to a staggering lack of transparency from HHS, AFGE Local...

What Is The Estimated Industry Size Of Oral Antidiabetic Drugs Market? The market size for oral antidiabetic medication has seen powerful growth in the past few years. The value is projected to rise from $62.25 billion in 2024 to $66.73 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. The past growth can be credited to the heightened occurrence of diabetes, better knowledge about managing the disease, an increase in the elderly population, expanded accessibility of advanced oral antidiabetic drugs, and developments in healthcare infrastructure. The market size for oral antidiabetic drugs is anticipated to experience robust growth in the upcoming years, reaching $86.92 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. The escalation for the projected period is tied to factors like the increasing utilization of new oral antidiabetic therapies, significant investments in diabetes research and development, growing demand for affordable diabetes management solutions, increasing instances of type 2 diabetes worldwide, and a heightened emphasis on personalized medicine for diabetes treatment. Anticipated trends for the forecast period consist of the progression in drug delivery technologies, pioneering efforts in composite therapies, adoption of digital health instruments for diabetes regulation, fabrication of safer and more...

Telehealth company Ro has tapped tennis star Serena Williams as a celebrity patient ambassador for its weight-loss treatments, the company said Thursday. The 23-time Grand Slam champion, who retired from professional tennis in 2022, will headline a multi-year national marketing campaign for GLP-1 drugs, a company spokesperson said. "I don't take shortcuts," Williams said in an NBC News interview, adding that her efforts to lose weight before turning to GLP-1 treatments included professional tennis training. "I was doing everything right ... but my body wasn't responding the way it used to," she said. Williams said in an advertisement that after struggling to lose post-baby weight, the treatments helped her lose 31 pounds (14 kg) - her first time speaking out about using them, Ro said. "Serena knows people may be surprised to learn that she would use a GLP-1, and that’s exactly why we think she is the perfect person to share her story," said a Ro spokesperson. Ro said Williams' husband Alexis Ohanian, the co-founder of social media site Reddit, is an investor in the company and serves on its board. GLP-1 drugs promote weight loss by reducing appetite and causing the stomach to empty more slowly. Novo Nordisk's Wegovy and Eli Lilly's Zepbound have...

The global irritable bowel syndrome (IBS) treatment market is experiencing a remarkable growth trajectory, with market value expected to soar from $1.07 billion in 2018 to $2.01 billion by 2026, registering a CAGR of 8.2% between 2019 and 2026. This upward trend is driven by the growing global prevalence of gastrointestinal disorders, aging populations, and an increasing demand for effective, targeted therapies. Understanding IBS: A Growing Health Challenge IBS is a chronic gastrointestinal disorder that impacts the large intestine, causing symptoms such as abdominal pain, bloating, gas, cramping, and irregular bowel habits. The condition is broadly categorized into three types—IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS—with IBS-D currently accounting for the largest share of diagnosed cases worldwide. Treatment strategies for IBS are multifaceted, combining dietary modifications, stress management, counseling, and pharmacological interventions. Medications such as rifaximin, eluxadoline, lubiprostone, linaclotide, and antispasmodics like peppermint oil and dicyclomine are widely prescribed, offering symptom relief and improving quality of life for patients.

The American Academy of Pediatrics on Tuesday recommended that all young children get vaccinated against COVID-19, differing from federal policy that no longer recommends routine COVID vaccination for healthy children. The U.S. pediatric group, in its latest policy document, said all young children aged 6-23 months receive a COVID-19 vaccine regardless of previous doses or SARS-CoV-2 infection, and recommended vaccination for older children in certain risk groups. The U.S. Centers for Disease Control and Prevention in May said COVID-19 vaccines are now an option for healthy children when parents and doctors agree that it is needed. Prior to the new guidance, the agency routinely recommended updated COVID vaccines for everyone aged six months and older, in line with the advice of its panel of outside experts. "Shared clinical decision-making (involving parents and doctors) can be difficult to implement because it lacks clear guidance and does not emphasize the importance of vaccinating people at high risk of severe disease," the AAP said in a statement. In early July, the AAP and other major medical groups sued Health and Human Services Secretary Robert Kennedy Jr. for unilaterally removing routine vaccination recommendations. The rate of COVID-19 hospitalization for children under 2 years is the highest among pediatric age...

Santhera Pharmaceuticals announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Sales are expected to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated in late 2026 following market authorisation and pricing agreement. Santhera will receive a percentage of net sales as payment, consistent with the company's previous distribution agreements. This agreement will help ensure that patients across these countries have timely access to this innovative therapy. Dario Eklund, chief executive officer of Santhera, said: “We are excited to partner with Uniphar for the distribution of AGAMREE in GCC (Gulf Cooperation Council) countries. Uniphar’s strong regional presence, combined with its proven expertise in early and expanded access programs, will help address the significant unmet need for boys and men living with DMD in these countries. This agreement represents another important step in our global expansion strategy and demonstrates our unwavering commitment to making effective rare disease treatments accessible to patients worldwide.” Santhera remains committed to the global rollout of AGAMREE,...

Medication prescribed to people with ADHD not only helps them focus but it also reduces the risk of suicidal behaviours, substance misuse, transport accidents and criminality, a study has found. It’s estimated 2.6 million people in the UK live with attention deficit hyperactivity disorder (ADHD), which affects around 5 per cent of children and 2.5 per cent of adults worldwide. But in the UK, just over half are prescribed medication for it. Researchers compared the impacts of medicating ADHD on those who have been recently diagnosed. Using data from Swedish national registers between 2007 and 2020 researchers at the Karolinska Institute, Sweden, were able to examine the effects of ADHD drug treatment in 148,581 individuals aged between six and 64-years-old over two years. Just over half (57 per cent) of participants had started drug treatment for ADHD, with methylphenidate – a type of stimulant – being the most commonly prescribed (88.4 per cent). However, the other people who were also newly diagnosed did not receive medication. The study, published by the BMJ, assessed how often those with ADHD had suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality, over two years after their diagnosis. After accounting for factors including age, sex, education level,...

The Kidney Transplant Market is expected to reach at a CAGR of 3.7% during the forecast period 2025-2033. The Global Kidney Transplant Market is witnessing growth due to rising kidney diseases, advanced surgical techniques, and increasing organ donation awareness worldwide.” — DataM Intelligence AUSTIN, TX, UNITED STATES, August 19, 2025 /EINPresswire.com/ -- Overview of the Market: The Global Kidney Transplant Market is experiencing robust growth, driven by the rising prevalence of chronic kidney diseases (CKD), end-stage renal disease (ESRD), and advancements in transplant technology. Kidney transplantation is considered the most effective treatment for patients with ESRD compared to dialysis, offering improved survival rates and quality of life. Increasing awareness about organ donation, government-backed initiatives, and expanding healthcare infrastructure are further boosting the market demand worldwide. According to DataM Intelligence, the Global Kidney Transplant Market was valued at USD 7.91 billion in 2024 and is expected to reach USD 10.99 billion by 2033, expanding at a CAGR of 3.7% between 2025 and 2033. The rising number of kidney failure cases due to diabetes and hypertension has created a high demand for transplants. North America dominates the market owing to advanced healthcare systems, strong regulatory frameworks, and higher organ donation rates, while the living donor transplant...